25th Feb 2026 Managing specific adverse effects of teclistamab in multiple myeloma patients: a plain language summary
28th Oct 2025 CEPHEUS study: daratumumab combination therapy for newly diagnosed multiple myeloma: plain language summary
15th Sep 2025 Plain language summary: testing sacituzumab govitecan in metastatic bladder cancer patients after immunotherapy when standard chemotherapy isn’t an option
15th Aug 2025 How isatuximab injections work when given under the skin to people with difficult-to-treat multiple myeloma: a plain language summary
8th Nov 2024 Final analysis of the GRIFFIN study: Daratumumab with lenalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma
24th Sep 2024 Plain language summary of the PERSEUS study on daratumumab combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma
15th Aug 2024 Plain language summary of the CARTITUDE-4 study on ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma
11th Jul 2023 Plain Language Summary: the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
23rd May 2023 Plain Language Summary: the MAIA study, daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
23rd Feb 2023 A plain language summary of daratumumab plus lenalidomide / bortezomib / dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
